Interactions between amphotericin B and nitroimidazoles against Candida albicans

Mycoses

Volumn 40, Issue 5-6, 1997, Pages 187-192

  Cury, Arlete Emily ^a   Hirschfeld, Marisa Porta Miche ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amphotericin B; Antifungal drug combinations; Candida albicans; Nitroimidazoles

Indexed keywords

AMPHOTERICIN B; ANTIPROTOZOAL AGENT; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; ORNIDAZOLE; POLYENE; SECNIDAZOLE; TINIDAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

CANDIDA ALBICANS;

EID: 0031472531     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.1997.tb00212.x     Document Type: Article

References (37)

1. Gupta, A. K., Sauder, D. N. & Shear, N. H. (1994) Antifungal agents: an overview. Part I. J. Am. Acad. Dermatol. 30, 677-700.
2. Graybill, J. R. (1992) Future directions of antifungal chemotherapy. Clin. Infect. Dis. 14 (suppl. 1), S170-S181.
3. Samonis, G. & Bafaloukos, D. (1992) Fungal infections in cancer patients: an escalating problem. In vivo 6, 183-193.
4. Swerdloff, J. N., Filler, S. G. & Edwards, J. E. Jr (1993) Severe candidal infections in neutropenic patients. Clin. Infect. Dis. 17 (suppl. 2), S457-S467.
5. Just-Nübling, G. (1996) Antifungal combination in the treatment of severe mycoses. 3rd meeting of the European Confederation of Medical Mycology, Lisbon, abstract 1.3.
6. Cameron, M. L., Shell, W. A., Bruch, S., Bartlett, J. A., Waskin, H. A. & Perfect, J. R. (1993) Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human in immunodeficiency virus type I. Antimicrob. Agents Chemother. 37, 2449-2453.
7. Cesaro, S., Rossetti, F., Perilongo, G., Rossi, L. & Zanesco, L. (1993) Fluconazole prophylaxis and Candida fungemia in neutropenic children with malignancies. Haematologia 37: 249-251.
8. Odds, F. C. (1993) Resistance of yeasts to azole-derivative antifungals. J. Antimicrob. Chemother. 31, 463-471.
9. Edwards, J. E. Jr & Filler, S. G. (1992) Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients. Clin. Infect. Dis. 14 (suppl. 1), S106-S113.
10. Grasela, T. H., Pasko, M. T., Goodwill, S. D., Walawander, C. A., Blackwelder, N. & Bruder-Holt, R. J. (1994) Use of antifungal therapy in hospitalized patients. II. Results after the marketing of fluconazole. Ann. Pharmacother 28, 261-270.
11. Hoeprich, P. D. (1992) Clinical use of amphotericin B and derivatives: lore, mystique and fact. Clin. Infect. Dis. 14 (suppl. 1), S114-S119.
12. Khoo, S. H., Bond, J. & Denning, D. W. (1994) Administering amphotericin B: a practical approach. J. Antimicrob. Chemother. 33, 203-213.
13. Klastersky, J. (1993) Febrile neutropenia. Support. Care Cancer 1, 233-239.
14. Barret, J. F. & Klaubert, D. H. (1992) Recent advances in antifungal agents. Annu. Rep. Med. Chem., 27, 149-158.
15. Petrou, M. A. & Rogers, T. R. (1991) Interactions in vitro between polyenes and imidazoles against yeasts. J. Antimicrob. Chemother. 27, 491-506.
16. Mc Ginnis, M. R. & Rinaldi, M. G. (1991) Antifungal drugs: mechanism of action, drug resistance, susceptibility testing, and assays of activity in biological fluids. In: Lorian, V. (ed) Antibiotics in Laboratory Medicine. Baltimore: Williams and Wilkins, pp. 198-257.
17. Thakur, R. K., Sckelcy, K. M., Kahn, R. N. & Cannon, L. (1994) Successful treatment of Candida prosthetic valve endocarditis with a combination of fluconazole and amphotericin B. Crit. Care Med. 22, 713.
18. Sugar, A. M., Salibian, M. & Goldani, L. Z. (1994) Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B. Antimicrob. Agents Chemother. 38, 371-373.
19. Meyer, R. D. (1992) Current role of therapy with amphotericin B. Clin. Infect. Dis. 14 (suppl. 1), S154-S160.
20. Ghannoum, M. A., Fu, Y., Ibrahim, A. S. et al. (1995) In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob. Agents Chemother. 39, 2459-2465.
21. Korolkovas, A. (1988) Essentials of Medical Chemistry. 2nd edn. New York: Wiley Interscience, pp. 579-869.
22. Lau, A. H., Lam, M. P., Piscitelli, S. C., Wilkes, L. & Danziger, L. H. (1992) Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin. Pharmacokinet. 23, 328-364.
23. Rossignol, J. F., Maisonneuve, H. & Cho, Y. W. (1984) Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis. Int. J. Clin. Pharmacol. Ther. Toxicol. 22, 63-72.
24. Dupont, B. (1966) Systemic mycoses in immunocompromised host. 3rd meeting of the European Confederation of Medical Mycology, Lisbon, abstract 1.1.
25. Kobayashi, G. S. & Medoff, G. (1983) Measurement of activity of antifungal drugs. In: Howard, D. H. and Howard, L. F. (eds) Fungi Pathogenic for Humans and Animals. Vol. 3, B-I. New York: Marcel Dekker, pp. 357-372.
26. Van Der Auwera, P. (1992) Synergistic, additive, and antagonistic activity of antimicrobial agents: how to measure? What are the clinical consequences? Application to the new fluoroquinolones. Infect. Dis. Newslett. 11, 45-56.
27. Berenbaum, M. C. (1978) A method for testing for synergy with any number of agents. J. Infect. Dis. 137, 122-130.
28. Odds, F. C. (1982) Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob. Agents Chemother. 22, 763-770.
29. Petersdorf, R. G. (1975) Combination antimicrobial therapy. West. J. Med. 123, 135-136.
30. Vanden Bossche, H., Willemsens, G. & Marichal, P. (1987) Anti-Candida drugs - the biochemical basis for their activity. CRC. Crit Rev. Microbiol. 15, 57-72.
31. Reese, R. E. & Betts, R. F. (1983) Antibiotic use. In: Reese, R. E. and Douglas, R. G. Jr (eds) A Practical Approach to Infectious Diseases. Boston: Little Brown, pp. 51-162.
32. Ghannoum, M. A., Abu-Elteen, K. H., Motawy, M. S., Abu-Hatab, M. A., Ibrahim, A. S. & Criddle, R. S. (1990) Combinations ot antifungal and antineoplastic drugs with interactive effects on inhibition of yeasts growth. Chemotheraphy 36, 308-320.
33. Medoff, G., Kobayashi, G. S., Kwan, C. N., Schlessinger, D. & Venkov, P. (1972) Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B. Proc. Natl Acad. Sci. USA 69, 196-199.
34. Shadomy, S., Wagner, G., Espinel-Ingroff, A. & Davis, B. A. (1975) In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob. Agents Chemother. 8, 117-121.
35. Kerridge, D. (1986) Mode of action of clinically important antifungal drugs. Adv. Microb. Physiol. 27, 1-72.
36. Brogden, R. N., Heell, R. C., Speight, T. M. & Avery, G. S. (1978) Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use. Drugs 16, 384-417.
37. Knight, R. C., Skolimowski, I. M. & Edwards, D. I. (1978) The interaction of reduced metronidazole with DNA. Biochem. Pharmacol. 27, 2089-2093.